EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under Nasdaq Listing Rule 5635(c)(4) to six new employees totaling 143,000 shares.

The options were granted on February 13, 2026, at an exercise price of $12.94 (closing price that day), have a 10-year term, and vest over four years (25% after one year, then monthly).

News Market Reaction – EYPT

+15.22% 2.7x vol

32 alerts

+15.22% News Effect

+30.0% Peak Tracked

-13.3% Trough Tracked

+$172M Valuation Impact

$1.30B Market Cap

2.7x Rel. Volume

On the day this news was published, EYPT gained 15.22%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.0% during that session. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $172M to the company's valuation, bringing the market cap to $1.30B at that time. Trading volume was elevated at 2.7x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 143,000 shares New employees: 6 Exercise price: $12.94 per share +4 more

7 metrics

Inducement options 143,000 shares Aggregate options granted to six new employees

New employees 6 Recipients of inducement stock option awards

Exercise price $12.94 per share Equal to closing price on February 13, 2026

Grant date February 13, 2026 Date options were granted

Option term 10 years Lifespan of inducement stock options

Vesting duration 4 years 25% after one year, remainder monthly over three years

Initial vesting 25% Cliff vest on first anniversary of grant date

Market Reality Check

Price: $15.33 Vol: Volume 790,193 vs 20-day ...

normal vol

$15.33 Last Close

Volume Volume 790,193 vs 20-day average 1,073,570 (relative volume 0.74x) ahead of this filing-style update. normal

Technical Shares at $12.94, trading above the 200-day MA of $12.05 before this inducement grant news.

Peers on Argus

Two tracked biotech peers, QURE and PRAX, appeared in momentum scans with moves ...

2 Up

Two tracked biotech peers, QURE and PRAX, appeared in momentum scans with moves of +1.76% and +5.72% respectively, but sector momentum overall was flagged as false, pointing to stock-specific drivers for EYPT.

Historical Context

5 past events · Latest: Feb 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Conference participation	Neutral	+3.2%	Announcement of CFO fireside chat at Guggenheim biotech summit with webcast access.
Jan 16	Inducement option grants	Neutral	-4.8%	Inducement options for three new employees totaling 13,900 shares under Rule 5635(c)(4).
Jan 07	Corporate milestones	Positive	+3.0%	Corporate update on DURAVYU Phase 3 enrollment, 2026 data timing, and cash runway.
Dec 17	Conference presentation	Neutral	-1.6%	CEO presentation scheduled at the 44th J.P. Morgan Healthcare Conference with webcast.
Dec 16	Inducement option grants	Neutral	+3.2%	Inducement options for nine new employees totaling 137,000 shares at market price.

Pattern Detected

Recent news—ranging from conference appearances to option inducements and a major 2026 milestones update—has often coincided with single‑digit percentage moves in both directions, with no clear pattern of selling on equity-compensation headlines.

Recent Company History

Over the last few months, EyePoint has mixed routine corporate communications with more substantial clinical and financial updates. A Jan 7, 2026 corporate update highlighted pivotal 2026 milestones and a strengthened cash position, followed by conference participation announcements at J.P. Morgan and Guggenheim events. The company has repeatedly issued NASDAQ Rule 5635(c)(4) inducement option grants in Dec 2025, Jan 2026, and now February, signaling ongoing hiring alongside its Phase 3 program execution.

Market Pulse Summary

The stock surged +15.2% in the session following this news. A strong positive reaction aligns with E...

Analysis

The stock surged +15.2% in the session following this news. A strong positive reaction aligns with EyePoint’s pattern of noticeable moves around corporate updates and equity-related announcements, where past news linked to options and milestones saw moves of 3.02% to 3.24%. This grant continues a series of NASDAQ Rule 5635(c)(4) inducement options tied to ongoing hiring. Investors monitoring sustainability would often weigh cumulative equity issuance alongside upcoming pivotal readouts and prior capital-raising activity.

Key Terms

non-statutory stock options, inducement awards, nasdaq listing rule 5635(c)(4), exercise price

4 terms

non-statutory stock options financial

"The Company granted non-statutory stock options to new employees as inducement..."

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

inducement awards financial

"granted non-statutory stock options to new employees as inducement awards outside..."

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq listing rule 5635(c)(4) regulatory

"outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The option awards have an exercise price of $12.94 per share..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 143,000 shares of EyePoint common stock to six new employees. The stock options were granted on February 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $12.94 per share, the closing price of EyePoint’s common stock on February 13, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What did EyePoint (EYPT) grant under Nasdaq Listing Rule 5635(c)(4) on February 13, 2026?

EyePoint granted non-statutory stock options to six new employees totaling 143,000 shares. According to the company, the options were approved by the Compensation Committee and granted as inducement awards outside the 2023 Long-Term Incentive Plan.

What is the exercise price and term of EyePoint's (EYPT) February 13, 2026 option grants?

The options have an exercise price of $12.94 and a ten-year term. According to the company, $12.94 was the closing price of EyePoint common stock on February 13, 2026.

How do the EyePoint (EYPT) option grants vest for the new employees?

The options vest over four years with 25% vesting after one year, then monthly thereafter. According to the company, vesting is subject to each employee's continued service through applicable vesting dates.

How many employees received inducement option awards from EyePoint (EYPT) and how many shares were involved?

Six new employees received inducement option awards covering an aggregate of 143,000 shares. According to the company, these were granted as material inducements to employment under Nasdaq rules.

Were EyePoint's (EYPT) inducement option grants approved by a company committee?

Yes, the grants were approved by the Compensation Committee before issuance. According to the company, the Committee approved the inducement awards in line with Nasdaq Listing Rule 5635(c)(4).

Do EyePoint's (EYPT) option awards require continued employment to vest?

Yes, vesting requires the employee to remain in service through each vesting date. According to the company, vesting occurs only while the employee continues service with EyePoint.